Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05372367 | A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor | completed | Phase 1 | 33 | Boehringer IngelheimINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 |
| clinicaltrials |
| NCT04627740 | Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06553157 | Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy | completed | Phase 1 / Phase 2 | 56 | Minia UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06556108 | ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT04175847 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 198 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04617314 | A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 67 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05174585 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 21 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05378737 | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection | completed | Phase 1 | 216 | Bio-Thera SolutionsINDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05774873 | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. | completed | Phase 1 / Phase 2 | 28 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05864573 | Study of ZGGS15 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 28 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04648254 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor | completed | Phase 1 | 51 | Qurient Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05025358 | A Study of LP-118 in Patients With Advanced Tumors | completed | Phase 1 | 68 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT04936178 | A Study of NB003 in Patients With Advanced Malignancies | completed | Phase 1 | 258 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 6 | Dec 22, 2025 | clinicaltrials |
| NCT05508334 | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 41 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03388632 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05240898 | A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors | completed | Phase 1 | 116 | Hoffmann-La RocheINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05287399 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | completed | Phase 1 | 18 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | completed | Phase 1 | 168 | AbbVieINDUSTRY | 10 | Dec 10, 2025 | clinicaltrials |
| NCT05417750 | A Phase I Study of GC101 TIL in Advanced Solid Tumors(MIZAR-001) | completed | Phase 1 | 43 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05105971 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China | completed | Phase 1 | 30 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05155722 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors | completed | Phase 1 | 59 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04021043 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05134948 | A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors(RELATIVITY 059) | completed | Phase 1 / Phase 2 | 24 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT06001580 | A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors | completed | Phase 1 | 15 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03486301 | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab(EIK1001) | completed | Phase 1 | 87 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04196530 | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab(EIK1001) | completed | Phase 1 | 40 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04840394 | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 1 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT05322408 | HCW9218 in Select Advanced Solid Tumors | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05847686 | Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | completed | Phase 1 / Phase 2 | 55 | University of WashingtonOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT03010176 | Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | completed | Phase 1 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 29, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02680795 | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | completed | Phase 1 | 17 | Acrotech Biopharma Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2026source: clinicaltrials